Ferrero, S
Pastore, A
Scholz, C W
Forstpointner, R
Pezzutto, A
Bergmann, L
Trümper, L
Finke, J
Keller, U
Ghione, P
Passera, R
Hiddemann, W
Weigert, O
Unterhalt, M
Dreyling, M
,
Article History
First Online: 5 August 2015
Competing interests
: Off-label use: Zevalin for the treatment of relapsed MCL. SF: Celgene-Mundipharma, Speakers Honoraria. LT: Spectrum Pharmaceuticals, research funding; CWS: Bayer, Speakers Bureau; Spectrum, Membership on an entity‘s Board of Directors or advisory committees, Speakers Honoraria. Gilead, Janssen-Cilag, Roche, Pfizer and Mundipharma, Advisory Board; Roche, Mundipharma, Pfizer and Gilead, Speakers Honoraria; UK: Spectrum Pharmaceuticals, Advisory board, Consultancy; Roche, Advisory board, Consultancy. MD: Jannsen-Celgene-Pfizer, Membership on an entity‘s Board of Directors or advisory committees, Speakers Bureau, support of ITS; Roche, Speakers Bureau, support of ITS; Mundipharma, support of ITS. The other authors declare no conflict of interest.